[go: up one dir, main page]

WO2007124331A3 - Cardioprotective and other uses of mammalian target of rapamycin (m-tor) inhibitors - Google Patents

Cardioprotective and other uses of mammalian target of rapamycin (m-tor) inhibitors Download PDF

Info

Publication number
WO2007124331A3
WO2007124331A3 PCT/US2007/066910 US2007066910W WO2007124331A3 WO 2007124331 A3 WO2007124331 A3 WO 2007124331A3 US 2007066910 W US2007066910 W US 2007066910W WO 2007124331 A3 WO2007124331 A3 WO 2007124331A3
Authority
WO
WIPO (PCT)
Prior art keywords
rapamycin
tor
inhibitors
cardioprotective
mammalian target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/066910
Other languages
French (fr)
Other versions
WO2007124331A2 (en
Inventor
Rakesh Kukreja
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virginia Commonwealth University
Original Assignee
Virginia Commonwealth University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Commonwealth University filed Critical Virginia Commonwealth University
Publication of WO2007124331A2 publication Critical patent/WO2007124331A2/en
Anticipated expiration legal-status Critical
Publication of WO2007124331A3 publication Critical patent/WO2007124331A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Novel uses of rapamycin include, e.g., the preconditioning-like effect of rapamycin against infarction in the intact heart as well against necrosis and apoptosis in cardiomyocytes. Other uses, especially in post-heart attack patients and other patients at risk of ischemia/reperfusion injury, are disclosed for rapamycin and other m-TOR inhibitors.
PCT/US2007/066910 2006-04-19 2007-04-19 Cardioprotective and other uses of mammalian target of rapamycin (m-tor) inhibitors Ceased WO2007124331A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74511206P 2006-04-19 2006-04-19
US60/745,112 2006-04-19

Publications (2)

Publication Number Publication Date
WO2007124331A2 WO2007124331A2 (en) 2007-11-01
WO2007124331A3 true WO2007124331A3 (en) 2008-10-23

Family

ID=38625721

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/066910 Ceased WO2007124331A2 (en) 2006-04-19 2007-04-19 Cardioprotective and other uses of mammalian target of rapamycin (m-tor) inhibitors

Country Status (1)

Country Link
WO (1) WO2007124331A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2416792A4 (en) * 2009-04-10 2012-10-24 Haiyan Qi NEW ANTI-AGING APPROACHES AND METHOD FOR IDENTIFYING THEM
JP5763098B2 (en) 2009-12-20 2015-08-12 アスチュート メディカル，インコーポレイテッド Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2013086359A1 (en) 2011-12-08 2013-06-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA3158996C (en) 2013-01-17 2024-06-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN105917229B (en) 2013-12-03 2019-04-26 阿斯图特医药公司 Methods and compositions for the diagnosis and prognosis of renal injury and renal failure
WO2016164854A1 (en) * 2015-04-09 2016-10-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2017277305A1 (en) 2016-06-06 2018-12-20 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040097538A1 (en) * 2000-06-16 2004-05-20 Wyeth Method of treating cardiovascular disease
US20040185048A1 (en) * 2000-09-14 2004-09-23 Beth Israel Deaconess Medical Center, Inc., A Massachusetts Corporation Modulation of IL-2- and IL-15-mediated T cell responses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040097538A1 (en) * 2000-06-16 2004-05-20 Wyeth Method of treating cardiovascular disease
US20040185048A1 (en) * 2000-09-14 2004-09-23 Beth Israel Deaconess Medical Center, Inc., A Massachusetts Corporation Modulation of IL-2- and IL-15-mediated T cell responses

Also Published As

Publication number Publication date
WO2007124331A2 (en) 2007-11-01

Similar Documents

Publication Publication Date Title
WO2007124331A3 (en) Cardioprotective and other uses of mammalian target of rapamycin (m-tor) inhibitors
WO2008118332A3 (en) Hydrazido-peptides as inhibitors of hcv ns3-protease
WO2009073808A3 (en) Compositions and methods to modulate cell membrane resealing
WO2008019124A8 (en) Heteroaryl compounds useful as inhibitors of e1 activating enzymes
WO2007106690A3 (en) Degenerate nucleobase analogs
WO2011139699A3 (en) 5' modified nucleosides and oligomeric compounds prepared therefrom
WO2008124148A3 (en) Sulfur compounds as inhiibitors of hepatitis c virus ns3 serine protease
WO2007092213A3 (en) Inhibitors of e1 activating enzyme
WO2009019614A3 (en) Meganuclease variants cleaving a dna target sequence from the human interleukin-2 receptor gamma chain gene and uses thereof
WO2009079412A3 (en) Reverse transcriptase inhibitors
WO2011066291A3 (en) Lyophilization methods, compositions, and kits
WO2009070645A8 (en) Indoles, derivatives, and analogs thereof and uses thereof
WO2007143204A3 (en) Compositions and methods for modifying cell surface glycans
WO2008027600A3 (en) Imatinib compositions
EP1943252A2 (en) Processes for the preparation of lyophilized pharmaceutically acceptable salts of pemetrexed diacid
WO2009008913A3 (en) P1-nonepimerizable ketoamide inhibitors of hcv ns3 protease
WO2009111586A3 (en) Autonomous in vitro evolution
WO2009035634A3 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
WO2008088779A3 (en) Solid state forms of 5-azacytidine and processes for preparation thereof
WO2006071777A3 (en) Soft tissue repair and regeneration using postpartum-derived cells and cell products
WO2007146813A3 (en) Pyridinone analogs as cell proliferation inhibitors
WO2008033887A3 (en) Methods for treating cancer
WO2007131973A3 (en) Compositions and methods for modulating the immune system
WO2008076618A3 (en) Freeze thaw methods for making polymer particles
WO2007089743A3 (en) Potassium channel inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07760871

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07760871

Country of ref document: EP

Kind code of ref document: A2